Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
9 hedge funds and large institutions have $780K invested in Plus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more ownership
Funds ownership: 0.46% → 0.46% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less capital invested
Capital invested by funds: $981K → $780K (-$201K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$18.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.96K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ATPW
Ashton Thomas Private Wealth
Scottsdale,
Arizona
|
-$18.9K |
| 2 |
JP Morgan Chase
New York
|
-$146 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
AIGH Capital Management
Baltimore,
Maryland
| $645K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $66.9K | +$4.96K | +155 | +7% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $37.4K | – | – | – |
|
|
TSS
4
Two Sigma Securities
New York
| $16.8K | +$18.7K | +583 | New |
|
5
BlackRock
New York
| $8K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5.5K | +$1.38K | +43 | +29% |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $152 | – | – | – |
|
|
SS
8
SBI Securities
Tokyo,
Japan
| $76 | +$96 | +3 | New |
|
9
Bank of America
Charlotte,
North Carolina
| $55 | – | – | – |
|
|
DB
10
Danske Bank
Copenhagen K,
Denmark
| $1 | – | – | – |
|
11
Group One Trading
Chicago,
Illinois
| $1 | – | – | – |
|
|
ATPW
12
Ashton Thomas Private Wealth
Scottsdale,
Arizona
| – | -$18.9K | -517 | Closed |
|
|
13
JP Morgan Chase
New York
| – | -$146 | -4 | Closed |
|
PSTV Hedge Fund Activity: Q4 2024 in Review
9 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2024, worth a combined $780K — down 20% from $981K a quarter earlier.
Fund positioning in PSTV was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $18.7K. The largest seller was Ashton Thomas Private Wealth, exiting entirely with an estimated $18.9K sold.
- 9 institutional investors held Plus Therapeutics (PSTV) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $780K of Plus Therapeutics stock for Q4 2024, down 20% quarter-over-quarter.
- 2 funds opened new Plus Therapeutics positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Plus Therapeutics buyer in Q4 2024 was Two Sigma Securities, an estimated $18.7K added.
- The largest Plus Therapeutics seller in Q4 2024 was Ashton Thomas Private Wealth, an estimated $18.9K sold.
Based on aggregated 13F filings for Q4 2024.